181 related articles for article (PubMed ID: 8387385)
41. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1).
Kakkar R; Raju RV; Sharma RK
Cell Mol Life Sci; 1999 Jul; 55(8-9):1164-86. PubMed ID: 10442095
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors.
Glass WF; Moore JB
Biochem Pharmacol; 1979 Apr; 28(7):1107-12. PubMed ID: 87197
[No Abstract] [Full Text] [Related]
43. Characterization of the cyclic nucleotide phosphodiesterase isoenzymes present in rat epididymal fat cells.
Schmitz-Peiffer C; Reeves ML; Denton RM
Cell Signal; 1992 Jan; 4(1):37-49. PubMed ID: 1571203
[TBL] [Abstract][Full Text] [Related]
44. Effect of 3-isobutyl-1-methylxanthine and zaprinast on non-adrenergic non-cholinergic relaxation in the rat gastric fundus.
Barbier AJ; Lefebvre RA
Eur J Pharmacol; 1992 Jan; 210(3):315-23. PubMed ID: 1377130
[TBL] [Abstract][Full Text] [Related]
45. Characterization of membrane-bound cyclic nucleotide phosphodiesterases from bovine aortic smooth muscle.
Ivorra MD; Le Bec A; Lugnier C
J Cardiovasc Pharmacol; 1992 Apr; 19(4):532-40. PubMed ID: 1380595
[TBL] [Abstract][Full Text] [Related]
46. Studies on the inhibition of phosphodiesterase-catalyzed cyclic AMP and cyclic GMP breakdown and relaxation of canine tracheal smooth muscle.
Polson JB; Krzanowski JJ; Fitzpatrick DF; Szentivanyi A
Biochem Pharmacol; 1978 Jan; 27(2):254-6. PubMed ID: 203292
[No Abstract] [Full Text] [Related]
47. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
Murray KJ; England PJ
Biochem Soc Trans; 1992 May; 20(2):460-4. PubMed ID: 1327922
[No Abstract] [Full Text] [Related]
48. Zardaverine as a selective inhibitor of phosphodiesterase isozymes.
Schudt C; Winder S; Müller B; Ukena D
Biochem Pharmacol; 1991 Jun; 42(1):153-62. PubMed ID: 1648920
[TBL] [Abstract][Full Text] [Related]
49. Effects of [N-(2-oxo-3,5,7-cycloheptatrien-1-yl)] aminooxoacetic acid ethyl ester (AY-25,674) on cyclic 3',5'-nucleotide formation and phosphodiesterase activity.
Pugsley TA; Lippmann W
Experientia; 1979 Jan; 35(1):88-90. PubMed ID: 217716
[TBL] [Abstract][Full Text] [Related]
50. Inhibition cyclic nucleotide phosphodiesterase by FPL 55712, an SRS-A antagonist.
Chasin M; Scott C
Biochem Pharmacol; 1978; 27(16):2065-7. PubMed ID: 214090
[No Abstract] [Full Text] [Related]
51. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
Van Inwegen RG; Salaman P; St Georgiev V; Weinryb I
Biochem Pharmacol; 1979 Apr; 28(8):1307-12. PubMed ID: 87199
[No Abstract] [Full Text] [Related]
52. Inhibition of low Km cyclic GMP phosphodiesterases and potentiation of guanylate cyclase activators by cicletanine.
Silver PJ; Buchholz A; Dundore RL; Harris AL; Pagani ED
J Cardiovasc Pharmacol; 1990 Sep; 16(3):501-5. PubMed ID: 1700224
[TBL] [Abstract][Full Text] [Related]
53. Effect of carbenoxolone on phosphodiesterase and prostaglandin synthetase activities.
Vapaatalo H; Lindén IB; Metsä-Ketelä T; Kangasaho M; Laustiola K
Experientia; 1978 Mar; 34(3):384-5. PubMed ID: 204509
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of granulocyte cAMP-phosphodiesterase by rolipram in vivo is not sufficient to protect the canine myocardium from reperfusion injury.
Simpson PJ; Schelm JA; Smallwood JK; Clay MP; Lindstrom TD
J Cardiovasc Pharmacol; 1992 Jun; 19(6):987-95. PubMed ID: 1376823
[TBL] [Abstract][Full Text] [Related]
55. Interaction of the catalytic subunit of protein kinase A with the lung type V cyclic GMP phosphodiesterase: modulation of non-catalytic binding sites.
Burns F; Pyne NJ
Biochem Biophys Res Commun; 1992 Dec; 189(3):1389-96. PubMed ID: 1336365
[TBL] [Abstract][Full Text] [Related]
56. Effects of amrinone and enoximone on the subclasses of cyclic AMP phosphodiesterase from human heart and kidney.
Masuoka H; Ito M; Nakano T; Naka M; Tanaka T
J Cardiovasc Pharmacol; 1990 Feb; 15(2):302-7. PubMed ID: 1689427
[TBL] [Abstract][Full Text] [Related]
57. Characterisation of cyclic nucleotide phosphodiesterases from rat mesenteric artery.
Komas N; Lugnier C; Andriantsitohaina R; Stoclet JC
Eur J Pharmacol; 1991 Sep; 208(1):85-7. PubMed ID: 1657622
[TBL] [Abstract][Full Text] [Related]
58. Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
Davey DD; Erhardt PW; Cantor EH; Greenberg SS; Ingebretsen WR; Wiggins J
J Med Chem; 1991 Sep; 34(9):2671-7. PubMed ID: 1654425
[TBL] [Abstract][Full Text] [Related]
59. Biochemical and electrical aspects of the tracheal relaxant action of AH 21-132.
Small RC; Berry JL; Boyle JP; Chapman ID; Elliott KR; Foster RW; Watt AJ
Eur J Pharmacol; 1991 Jan; 192(3):417-26. PubMed ID: 1647318
[TBL] [Abstract][Full Text] [Related]
60. Differentiation of intestinal smooth muscle relaxation caused by drugs that inhibit phosphodiesterase.
Pöch G; Umfahrer W
Naunyn Schmiedebergs Arch Pharmacol; 1976 Jun; 293(3):257-68. PubMed ID: 183155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
